The use of left bundle branch area pacing (LBBAP) is growing in electrophysiology implanted devices. Two late-breaking studies at Heart Rhythm 2023 highlight the success of LBBAP as an alternative to the standard of care using biventricular pacing.

The newly approved device is powered by Bluetooth technology and available with a three- or six-year battery.

The new drug, asundexian, is currently the subject of two multicenter Phase III studies—the OCEANIC-AF trial and OCEANIC-STROKE trial—focused on its safety and efficacy.

“These and other data support that young adults do as well as a more traditional patient population when looking at arrhythmia-free survival,” researchers wrote.

Heart Rhythm 2023, the society's 44th annual meeting, is scheduled for May 19-21. 

Samsung's smartwatches, already equipped with ECG technology, will now be able to alert users when signs of an irregular heart rhythm are detected. 

The two new leadless pacemakers, the Micra AV2 and Micra VR2, feature much longer batteries than previous models. 

Patients with severe COVID-19 cases that required ventilation were 16 times more likely to develop ventricular tachycardia within six months, researchers found.